Theolytics' Ongoing US Phase 1 OCTOPOD-IP Trial Of THEO-260 In Ovarian Cancer To Be Presented As A Trial In Progress At ASCO 2026

(MENAFN - GlobeNewsWire - Nasdaq) THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in ...